Bionano Genomics (BNGO) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Seer (SEER) has outperformed Bionano Genomics (BNGO) over the past year, losing 3.6% versus a loss of 32.6%. Over five years, SEER leads with a -93.4% price change compared with -100.0% for BNGO. Seer is the larger company by market cap ($121.3 million vs $16.9 million), about 7.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | SEER |
|---|---|---|
| Share price | $1.44 | $2.19 |
| Market cap | $16.90M | $121.26M |
| 1-day change | -1.71% | +0.92% |
| YTD return | -6.21% | +18.58% |
| 1-year return | -32.63% | -3.56% |
| 5-year return | -99.95% | -93.42% |
| EPS (TTM) | $-3.02 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $2.41 |
| 52-week low | $1.00 | $1.55 |
| Distance from 52-week high | -35.65% | -9.13% |
| Analyst consensus | none | none |
| Avg. price target upside | +248.43% | +82.65% |
| Average volume | 921.59K | 479.14K |
| Shares outstanding | 11.78M | 55.37M |
| Employees | 95 | 124 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Seer is about 7.2 times larger than Bionano Genomics by market value ($121.26M vs $16.90M).
- SEER has outperformed BNGO by 29.1 percentage points over the past year.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
BNGO vs SEER FAQ
Which is bigger, Bionano Genomics or Seer?
Seer (SEER) is larger, with a market capitalization of $121.26M compared with $16.90M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or SEER?
SEER returned -3.56% over the past 12 months, compared with -32.63% for BNGO (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Seer in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.